After a fruitful clinical preliminary, Drug monster Eli Lilly looks for endorsement for its diabetes medication to get added to the U.S. weight loss market.
The decision was based on a recent clinical trial that demonstrated encouraging results, and the leading pharmaceutical company Eli Lilly announced its plans to seek approval for Tirzepatide, a diabetes medication, to be added to the weight loss market in the United States on Thursday. Once a week, an injection of tirzepatide, also known as Mounjaro, is given to treat type 2 diabetes.
The outcomes of the trial
A clinical trial that lasted 72 weeks and was conducted by Eli Lilly included over 900 people who were overweight or obese and had type 2 diabetes. The highest-dose participants lost an average of 34.4 pounds (15.6 kilograms) or 15.7% of their body weight. The maximum commonplace aspect outcomes have been slight to mild gastrointestinal troubles like nausea and diarrhea.
In the coming weeks, Eli Lilly is anticipated to submit an application for approval to American authorities, and the company anticipates regulatory action by the end of 2023. Weight loss of approximately 21% was observed among overweight and obese participants without diabetes in a previous clinical trial.
tirzepatide mimics the gastrointestinal hormone glp-1 and activates receptors inside the mind that alter urge for food. Experts generally consider the GLP-1 analogs to be a breakthrough because they result in significantly greater weight loss than previous medications. Some doctors are already prescribing tirzepatide for weight loss, which was first approved for diabetes treatment in the United States in May 2022.
With 40% of Americans believed to be obese, this presents a promising economic opportunity for the pharmaceutical industry. Morgan Stanley predicts that the worldwide market for stoutness medicines might reach $54 billion by 2030.
Concerns and competition
Novo Nordisk's Wegovy, which uses semaglutide, another drug that mimics GLP-1, has already received FDA approval in the United States for weight loss. However, supply issues and high prices have made it difficult for many individuals to obtain Ozempic, the company's diabetes medication that also makes use of semaglutide.
Experts are concerned that these drugs might be used by people who are not clearly overweight to lose a few pounds. Additionally, the medications are intended for long-term use, and once treatment is stopped, there is a possibility of regaining weight.
Eli Lilly's Tirzepatide medication might give a clever treatment choice to individuals doing combating weight and type 2 diabetes. The drug could become a major contender in the weight loss industry if the company's application for approval is approved. However, in order to achieve long-term, sustainable weight loss, it is essential to use the medication correctly and under medical supervision.
0 Comments